BR112017001966A2 - ?método para produzir variantes com um fc com sialilação melhorada? - Google Patents

?método para produzir variantes com um fc com sialilação melhorada?

Info

Publication number
BR112017001966A2
BR112017001966A2 BR112017001966A BR112017001966A BR112017001966A2 BR 112017001966 A2 BR112017001966 A2 BR 112017001966A2 BR 112017001966 A BR112017001966 A BR 112017001966A BR 112017001966 A BR112017001966 A BR 112017001966A BR 112017001966 A2 BR112017001966 A2 BR 112017001966A2
Authority
BR
Brazil
Prior art keywords
fragment
improved
sialylated
producing variants
mutating
Prior art date
Application number
BR112017001966A
Other languages
English (en)
Inventor
Fontayne Alexandre
MONNET Céline
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BR112017001966A2 publication Critical patent/BR112017001966A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção refere-se a um método para aumentar a sialilação de um fragmento fc, compreendendo um passo de mutação de pelo menos um aminoácido selecionado de entre os aminoácidos nas posições 240 a 243, 258 a 267 e 290 a 305 do referido fragmento fc, sendo a numeração a do índice da ue ou equivalente em kabat. a presente invenção também se refere a um método para produzir uma variante de um polipeptídeo parente compreendendo um fragmento fc, tendo a referida variante sialilação melhorada do fragmento fc relativamente ao polipeptídeo parente, que compreende um passo de mutação de pelo menos um aminoácido selecionado de entre os aminoácidos nas posições 240 a 243, 258 a 267 e 290 a 305 do referido fragmento fc, sendo a numeração a do índice da ue ou equivalente em kabat.
BR112017001966A 2014-08-01 2015-07-31 ?método para produzir variantes com um fc com sialilação melhorada? BR112017001966A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1457504A FR3024453B1 (fr) 2014-08-01 2014-08-01 Procede de production de variants ayant un fc presentant une sialylation amelioree
PCT/FR2015/052123 WO2016016586A1 (fr) 2014-08-01 2015-07-31 Procédé de production de variants ayant un fc présentant une sialylation améliorée

Publications (1)

Publication Number Publication Date
BR112017001966A2 true BR112017001966A2 (pt) 2017-11-21

Family

ID=51987257

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017001966A BR112017001966A2 (pt) 2014-08-01 2015-07-31 ?método para produzir variantes com um fc com sialilação melhorada?

Country Status (11)

Country Link
US (1) US20170260254A1 (pt)
EP (1) EP3174904A1 (pt)
JP (1) JP2017522040A (pt)
KR (1) KR20170035923A (pt)
CN (1) CN106573978A (pt)
AU (1) AU2015295090A1 (pt)
BR (1) BR112017001966A2 (pt)
CA (1) CA2956822A1 (pt)
FR (1) FR3024453B1 (pt)
MX (1) MX2017001516A (pt)
WO (1) WO2016016586A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7464389B2 (ja) 2016-08-02 2024-04-09 ビステラ， インコーポレイテッド 操作されたポリペプチドおよびその使用
FR3058159B1 (fr) * 2016-10-28 2022-02-25 Lab Francais Du Fractionnement Variants de polypeptide fc presentant une demi-vie augmentee
FR3064007A1 (fr) * 2017-03-20 2018-09-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps pour le traitement de cancers
FR3075200B1 (fr) * 2017-12-15 2022-12-23 Lab Francais Du Fractionnement Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
FR3080376B1 (fr) * 2018-04-20 2022-12-09 Lab Francais Du Fractionnement Autoanticorps hautement sialyles et leurs utilisations
CN114829407B (zh) * 2019-09-23 2024-06-21 南开大学 利用哺乳动物展示筛选FcγR特异性结合Fc
EP4446345A1 (en) * 2021-12-09 2024-10-16 Shanghai Bao Pharmaceuticals Co., Ltd. Fc polypeptide having altered glycosylation modification

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601822A1 (de) 1986-01-22 1987-07-23 Peter Stenzel Mit einem druckmedium arbeitende betaetigungsvorrichtung
FR2816319B1 (fr) 2000-11-08 2004-09-03 Millegen Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires
JP2008504008A (ja) * 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
SG163548A1 (en) * 2005-06-30 2010-08-30 Centocor Inc Methods and compositions with enhanced therapeutic activity
EP2708557A1 (en) * 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
WO2011149999A2 (en) * 2010-05-27 2011-12-01 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
EP2409712A1 (en) * 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
MX352889B (es) * 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
CA2834589A1 (en) * 2011-05-25 2012-11-29 Merck Sharp & Dohme Corp. Method for preparing fc-containing polypeptides having improved properties
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
EP4234577A3 (en) * 2012-04-25 2023-10-18 Momenta Pharmaceuticals, Inc. Modified glycoproteins

Also Published As

Publication number Publication date
WO2016016586A1 (fr) 2016-02-04
FR3024453B1 (fr) 2018-06-29
US20170260254A1 (en) 2017-09-14
FR3024453A1 (fr) 2016-02-05
CN106573978A (zh) 2017-04-19
JP2017522040A (ja) 2017-08-10
CA2956822A1 (fr) 2016-02-04
EP3174904A1 (fr) 2017-06-07
KR20170035923A (ko) 2017-03-31
MX2017001516A (es) 2017-05-19
AU2015295090A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
BR112017001966A2 (pt) ?método para produzir variantes com um fc com sialilação melhorada?
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112018006254A2 (pt) camada implantável que compreende uma configuração constrita
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
BR112017023862A2 (pt) anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
BR112017019170A2 (pt) métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia
BR112017000521A2 (pt) polipeptídeo, composição imunogênica, e, método para aumentar uma resposta ao anticorpo.
BR112017004231A2 (pt) processo para produzir um precipitado estável enriquecido em ficobiliproteínas
BR112015017606A2 (pt) composição, método de produzir a composição, utilização da composição e combustível obtido a partir da composição
BR112016029157A2 (pt) processo para purificar a proteína de fusão tnfr:fc
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112018010160A2 (pt) inibidor da c1 esterase humana recombinante e usos do mesmo
BR112017008962A2 (pt) proteínas de fusão inibidoras de c1 esterase e usos das mesmas
PE20181176A1 (es) Composiciones biofarmaceuticas
BR112015018335A2 (pt) Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas
BR112017010453A2 (pt) composição adesiva com mudança de cor
BR112016015678B1 (pt) Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica
BR112016016103A2 (pt) Composição de antígenos micobacterianos
BR112017010804A2 (pt) polímero em multi-estágio, sua composição, seu método de preparação, seu uso e composição compreendendo o mesmo
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
BR112018006724A2 (pt) ácido caurenoico hidroxilases
BR112016002462A8 (pt) Métodos para melhorar os sintomas da asma usando benralizumabe
BR112019006310A2 (pt) método para fabricar digliceróxido de cálcio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements